The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Sasanlimab in combination with Bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non-muscle-invasive bladder cancer (HR NMIBC): Exploratory analysis of patients with very HR (VHR) disease from the phase 3 CREST trial
Xylinas E, Steinberg GD, Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Puente J, Hafron JM, Lodde M, Hamzaj A, Briganti A, Kulkarni GS, Brinkmann J, Calella A-M, Cesari R, Michelon E, Vermette J, Wei C, Guerrero-Ramos F
Poster
Immune-mediated adverse events (imAEs) associated with sasanlimab in combination with Bacillus Calmette-Guérin (BCG): Phase 3 study (CREST)
Bedke J, Shore N, Powles T, Galsky M, Palou Redorta J, Kretkowski M, Jiang S, Williams M, Uchio E, Falkowski S, Rodriguez Faba O, Cesari R, Vermette J, Calella A, Brinkmann J, Wei C, Michelon E, Steinberg G
Poster
Sasanlimab in combination with Bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC): Patient-reported outcomes (PROs) from CREST
Bedke J, Powles T, Galsky M, Redorta J, Shore N, Guerrero-Ramos F, Todenhöfer T, Black P, Satkunasivam R, Saltzstein D, Nakamura M, Vermette J, Brinkmann J, Reisman A, Chang J, Eccleston A, Steinberg G
Poster
Quantifying Patient Preferences for Bacillus Calmette-Guérin (BCG) and PD-(L)1 Inhibitors in High-risk Non-muscle Invasive Bladder Cancer: A Discrete
Hallworth P, Eccleston A, Mason B , Hauber B, Bell B, Coulter J, Lisa Marin L, Thompson A, Jones J, Chang J, Ayala-Nunes L, Brinkmann J, Guest C, Gater A, Koshy A, Cappelleri J, Chisolm S, Satkunasivam R
Presentation
Sasanlimab in combination with Bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC): Subgroup analyses from the CREST study
Powles T, Galsky M, Shore N, Redorta J, Bedke J, Xylines E, Lodde M, Hafron J, Vazquez J, Hamzaj A, Hu H, Cesari R, Vermette J, Calella A, Brinkmann J, Wei C, Steinberg G
Presentation
Sasanlimab in combination with Bacillus Calmette-Guérin improves event-free survival versus Bacillus Calmette-Guérin as standard of care in high-risk non-muscle-invasive bladder cancer: Phase 3 CREST study results
Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD